2018 IPO

PhaseBio Pharmaceuticals Stock

Developing drugs for cardiovascular diseases, endocrine and metabolic disorders

Sign up today and learn more about PhaseBio Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About PhaseBio Pharmaceuticals Stock

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects and better patient compliance. Efficient production in E. coli ensures low cost of goods. PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. A second drug candidate, Vasomera™, is currently being evaluated in a phase 1 clinical trial and has potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. A third program, Insumera, a basal insulin based on native human insulin, will enter clinical trials in early 2013. PhaseBio is based in Malvern, Pennsylvania.

Funding History

February 2002$0
October 2007$6.6M
November 2009$1.0M
January 2010$25.0M
June 2012$23.0M
March 2015$40.0M
November 2017$7.5M
February 2018$2.8M
September 2018$34.0M



Christopher Prior

Executive Chairman & CSO

Craig A. Rosen

Senior Vice President of Clinical Development

Lynne Georgopoulos


Joel Sussman

Chief Business Office

Jonathan Mow

Vice President, Scientific Affairs

Jim Ballance

Vice President of Preclinical and Assay Development

Susan Arnold

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: